ArticleBritish journal of clinical pharmacology2020
Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey.
Article in British journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Radiomodulatory and antioxidant properties of a novel pyrazine-linked quinazolinone sulfonamide derivative: Insights into renal apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Synthesis and characterization of bifunctional nanoprobes for targeted photodynamic therapy in breast cancer treatment.Discover nano · 2026Article
- US Food and Drug Administration black box warnings: Characteristics of drug classes and adverse effects.The Journal of pharmacology and experimental therapeutics · 2026Article
- Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.Pharmacological reviews · 2026Review
- Article
- Determinants of Adverse Events in Patients with Cancer Who Practiced Self-Medication: A Cross-Sectional Study in Southwestern Uganda.Cancer management and research · 2026Article
- Observational
- Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis.Immunotherapy · 2025Article
- Article
- Concordance between patient-reported outcomes and CTCAE clinician-reported toxicities during outpatient chemotherapy courses: a retrospective cohort study in routine care.ESMO real world data and digital oncology · 2025Article
- Review
- Exploring Usability of a Clinical Decision Support System for Cancer Care: A User-Centered Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Article
- Temporal Association Rule Mining: Race-Based Patterns of Treatment-Adverse Events in Breast Cancer Patients Using SEER-Medicare Dataset.Biomedicines · 2024Article
- Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol.Diagnostics (Basel, Switzerland) · 2024Article
- The application of Global Trigger Tool in monitoring antineoplastic adverse drug events: a retrospective study.Frontiers in oncology · 2024Article
- Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data.Cancers · 2023Article
- Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
aimsPharmaco-epidemiological surveys enable the frequency of serious adverse effects-and also the determining factors of their occurrence and seriousness-to be quantified. Few studies systematically gathering post-chemotherapy adverse effects data have been conducted. The objective was to assess the incidence of post-chemotherapy serious adverse effects on the basis of cancer registry data.
methodsThe population was composed of new invasive cancer cases, with the exception of haematopoietic tumours and cutaneous carcinomas. These cancers were identified in 2012 among patients living at the time of diagnosis in a region covered by a general cancer registry and by a French regional pharmacovigilance centre, and treated with neo-adjuvant and/or adjuvant first-intention chemotherapy, followed or not by radiotherapy. The study was based on a sample of 1000 patients from the registry, followed by the collection of serious adverse effects and the required information to constitute a pharmacovigilance file.
resultsChemotherapy was associated with a particularly high incidence of serious adverse effects, affecting 44.5% (41.4-47.5%) of the patients. The highest incidence rates were observed when patients were exposed to topo-isomerase II inhibitors such as etoposide and bleomycin (69.2%), vinca-alkaloids (66.7%), topo-isomerase I inhibitors (54.5%) and platinum derivatives (52.0%). The clinical context was also linked to incidence, especially in case of metastases (53.3%) and comorbidities (51.3%). Substantial differences were found according to localisation, with a particularly high incidence in bronchial-pulmonary cancers (59.0%).
conclusionThe high overall incidence rate of serious adverse effects should motivate a reinforcement of information about drug toxicities and improve knowledge by drawing on patient reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.